Edgestream Partners L.P. Has $2.79 Million Holdings in Guardant Health, Inc. (NASDAQ:GH)

Edgestream Partners L.P. raised its position in Guardant Health, Inc. (NASDAQ:GH) by 105.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 96,513 shares of the company’s stock after purchasing an additional 49,574 shares during the quarter. Edgestream Partners L.P. owned 0.08% of Guardant Health worth $2,787,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Principal Financial Group Inc. raised its position in Guardant Health by 10.5% in the 4th quarter. Principal Financial Group Inc. now owns 13,045 shares of the company’s stock valued at $353,000 after buying an additional 1,240 shares during the last quarter. Oak Ridge Investments LLC raised its holdings in shares of Guardant Health by 8.5% in the first quarter. Oak Ridge Investments LLC now owns 18,540 shares of the company’s stock valued at $382,000 after purchasing an additional 1,451 shares during the last quarter. Canton Hathaway LLC bought a new stake in shares of Guardant Health in the second quarter worth $59,000. Arizona State Retirement System boosted its holdings in Guardant Health by 7.5% during the second quarter. Arizona State Retirement System now owns 34,073 shares of the company’s stock worth $984,000 after purchasing an additional 2,383 shares during the last quarter. Finally, ProShare Advisors LLC grew its position in Guardant Health by 9.4% in the first quarter. ProShare Advisors LLC now owns 29,317 shares of the company’s stock valued at $605,000 after purchasing an additional 2,518 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Stock Down 0.0 %

GH opened at $25.08 on Thursday. The stock has a fifty day moving average of $29.10 and a 200-day moving average of $24.97. The company has a market capitalization of $3.07 billion, a P/E ratio of -6.40 and a beta of 1.11. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $37.04. The company has a debt-to-equity ratio of 16.70, a quick ratio of 6.07 and a current ratio of 6.40.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.10). Guardant Health had a negative return on equity of 418.21% and a negative net margin of 76.23%. The business had revenue of $177.24 million during the quarter, compared to analyst estimates of $162.59 million. During the same quarter last year, the firm earned ($0.67) EPS. Guardant Health’s revenue for the quarter was up 29.2% compared to the same quarter last year. On average, equities analysts expect that Guardant Health, Inc. will post -3.3 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on GH. Craig Hallum boosted their price target on shares of Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. The Goldman Sachs Group boosted their price objective on shares of Guardant Health from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, July 17th. Canaccord Genuity Group lifted their price target on Guardant Health from $30.00 to $38.00 and gave the stock a “buy” rating in a report on Tuesday, June 4th. JPMorgan Chase & Co. upped their price objective on Guardant Health from $45.00 to $48.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. Finally, Piper Sandler boosted their target price on Guardant Health from $30.00 to $34.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $39.31.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.